Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347430 | 0.84 | FABP4 (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2GLA | |
| SCHEMBL17347402 | 0.84 | KDM1A (0.61) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL17347485 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2GLA | |
| SCHEMBL27856511 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2GLA | |
| SCHEMBL27421449 | 0.80 | MAPT (0.60) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL17331311 | 0.80 | KDM1A (0.70) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL17331331 | 0.79 | LMNA (0.60) | MEN1KMT2ALMNA | |
| SCHEMBL17343057 | 0.78 | TSHR (0.62) | ALDH1A1MEN1KMT2ASMN1; SMN2GLA | |
| SCHEMBL17331308 | 0.76 | KMT2A (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2825815 | 0.76 | SMN1; SMN2 (0.58) | ALDH1A1MEN1KMT2ASMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | ALDH1A1 4655/4885MEN1 4396/4885KMT2A 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.